E3 PreliminaryPreliminaryPEM unclearObservationalPeer-reviewedMachine draft
Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome.
Kaushik, N, Fear, D, Richards, S C M et al. · Journal of clinical pathology · 2005 · DOI
Quick Summary
Researchers compared blood cells from 25 ME/CFS patients with 25 healthy people to see if genes were turned on or off differently. They found 16 genes with different activity levels in ME/CFS patients—most were overactive. These changes suggest problems with immune cell activation, nerve function, and how cells produce energy, which could help explain why ME/CFS causes fatigue and other symptoms.
Why It Matters
This study provides molecular evidence that ME/CFS involves measurable, reproducible changes in immune and cellular function, moving beyond purely subjective symptom reporting. Identifying specific dysregulated genes offers potential biomarkers and targets for future diagnostic tests and therapeutic interventions.
Observed Findings
- Sixteen genes showed reproducible differential expression confirmed by real-time PCR, with 15 upregulated and 1 downregulated in ME/CFS patients compared to controls.
- Upregulation of neuropathy target esterase (NTE) and eukaryotic translation initiation factor 4G1 (EIF4G1) was observed.
- The gene expression profile indicates T cell activation in peripheral blood.
- Mitochondrial and neuronal function-related genes showed perturbation.
- Downregulation of IL-10RA (interleukin-10 receptor alpha) was confirmed.
Inferred Conclusions
- ME/CFS patients have reproducible alterations in gene regulation detectable in peripheral blood mononuclear cells.
- The expression pattern suggests dysregulation of T cell immunity, mitochondrial function, and neuronal pathways.
- Possible links exist between the observed gene expression changes and viral infection or organophosphate exposure.
Remaining Questions
- Do these gene expression changes occur at disease onset or develop over time, and are they stable or fluctuating?
- Are these gene expression abnormalities specific to ME/CFS or shared with other conditions?
What This Study Does Not Prove
This study does not prove these gene expression changes cause ME/CFS—they may be consequences of the disease or occur alongside it. It does not establish whether these changes are unique to ME/CFS or present in other conditions, nor does it demonstrate that correcting these gene expression patterns would improve symptoms. The small sample size and single timepoint limit generalizability.
Tags
Symptom:Fatigue
Biomarker:Gene ExpressionBlood Biomarker
Method Flag:Small SampleExploratory Only
Metadata
- DOI
- 10.1136/jcp.2005.025718
- PMID
- 16049284
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →